AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)

Mount Carmel Register

Oct 15, 2021

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) |!| Mount Carmel